FDA PCAC Review February 2027: What It Means for Peptide Access

The FDA's Pharmacy Compounding Advisory Committee (PCAC) meets approximately twice per year to review the bulk-drug substances nominated for the 503A and 503B bulks lists — the lists that determine which active pharmaceutical ingredients can be used in compounded medications.

The February 2027 meeting will review several peptides currently on the Personalized Peptides catalog. The outcomes will directly affect whether these compounds remain accessible through compounding pharmacies.

The Regulatory Framework

Compounded medications exist in a different regulatory category than FDA-approved drugs. A 503A compounding pharmacy can compound a drug using bulk substances that appear on the FDA's 503A Bulks List, or that are components of FDA-approved drugs. A 503B outsourcing facility operates under similar but distinct rules with additional quality requirements.

Peptides that are not on the bulks list and are not components of approved drugs cannot legally be compounded — at least, not without the FDA exercising enforcement discretion. The PCAC reviews nominations for the bulks list and makes recommendations to the FDA. The FDA is not bound by PCAC recommendations, but it rarely contradicts them.

What Happened in April 2026

In April 2026, the FDA removed several peptides from Category 2 of the bulks list nomination process. GHK-Cu was among those removed — it is now under active PCAC review for the February 2027 meeting, with a specific focus on the injectable route. Topical GHK-Cu is Category 1 (not affected by the PCAC review).

The April action was significant: it signaled that the FDA is actively narrowing the list of compounds it will allow to be compounded, not passively maintaining an open-door policy. The February 2027 meeting is expected to continue this tightening trend.

What's on the February 2027 Agenda

Multiple peptides from the Personalized Peptides catalog are under review:

GHK-Cu (injectable route). Removed from Category 2 in April. Under second PCAC review for injectable compounding eligibility. The topical route is Category 1 and unaffected.

Melanotan-2. Under PCAC review. Safety concerns dominate the discussion — unregulated sunless tanning use, potential melanoma risk, and challenging risk-benefit for cosmetic applications.

BPC-157. Not currently on the bulks list. Regulatory status uncertain — the strong preclinical evidence base may support a future nomination, but no formal PCAC review is scheduled for February 2027.

Additional compounds under review include several GLP-1 agonists (semaglutide, tirzepatide), which face a different regulatory question — whether they can be compounded at all given the existence of FDA-approved versions (Ozempic, Wegovy, Mounjaro, Zepbound).

What the Outcomes Could Be

For each compound under review, the PCAC will recommend one of:

• Place on the bulks list. The compound can be legally compounded by 503A and/or 503B facilities. This is the best-case outcome for access.
• Do not place on the bulks list. The compound cannot be legally compounded using bulk substances. It may still be available as a research chemical through independent vendors, but compounding-pharmacy access is closed.
• Deferred. The committee requests more data and defers the decision to a future meeting.

What This Means for You

If you're currently using any peptide that is under PCAC review, the prudent course is:

• Stay informed. The PCAC meeting materials are published on the FDA website 2–3 days before the meeting. The agenda and nomination documents will identify exactly which compounds are being reviewed and what data the committee will consider.
• Don't stockpile. Peptides have finite shelf life even as lyophilized powder. Stockpiling based on regulatory uncertainty is a poor risk-management strategy.
• Plan alternatives. For any peptide in your protocol that may lose compounding access, identify alternatives — either a different compound with a similar mechanism, or a different delivery route (e.g., topical GHK-Cu as a fallback for injectable).
• Work with a clinician. The best defense against regulatory uncertainty is a relationship with a licensed clinician who can prescribe both compounded and pharmaceutical options, and who understands the regulatory landscape well enough to navigate it.

For understanding the broader regulatory vocabulary, see Understanding Peptide Research: What the Labels Mean. For evaluating whether a vendor's quality claims are legitimate, see Peptide Safety: How to Evaluate Research Chemical Quality.